Author:
Scaltriti M,Verma C,Guzman M,Jimenez J,Parra J L,Pedersen K,Smith D J,Landolfi S,Ramon y Cajal S,Arribas J,Baselga J
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference62 articles.
1. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J et al. (2003). ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274–1283.
2. Arteaga CL, Ramsey TT, Shawver LK, Guyer CA . (1997). Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 272: 23247–23254.
3. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX et al. (2004). Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268–5282.
4. Baselga J . (2006). Targeting tyrosine kinases in cancer: the second wave. Science 312: 1175–1178.
5. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J . (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825–2831.
Cited by
367 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献